A study to assess the absorption of eliglustat through the mouth in healthy subjects and the safety of any systemic exposure resulting from oral surface absorption of eliglustat in healthy subjects.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Plasma pharmacokinetic (PK) parameter: Cmax
Timeframe: Multiple timepoints on Day 1
Plasma pharmacokinetic (PK) parameter tmax
Timeframe: Multiple timepoints on Day 1
Plasma pharmacokinetic (PK) parameter AUClast
Timeframe: Multiple timepoints on Day 1
Plasma pharmacokinetic (PK) parameter AUC 0-2h
Timeframe: Multiple timepoints on Day 1
Plasma pharmacokinetic (PK) parameter AUC 2-4h
Timeframe: Multiple timepoints on Day 1
Plasma pharmacokinetic (PK) parameter AUC 4-6h
Timeframe: Multiple timepoints on Day 1
Plasma pharmacokinetic (PK) parameter tlast
Timeframe: Multiple timepoints on Day 1